New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...
The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
An open letter to US Secretary of State Marco Rubio signed by hundreds of high-profile HIV doctors, researchers and public ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...
The Punch on MSN18h
USAID cuts causing ‘catastrophic harm’ doctors tell TrumpHundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...
Health and Me on MSN1h
Yearly Jab For HIV Protection Is Now Almost HereThe injectable drug, Lenacapavir, works by stopping the virus from replicating inside cells, potentially offering a long-term ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback